Biohaven price target lowered to $26 from $27 at UBS

UBS lowered the firm’s price target on Biohaven (BHVN) to $26 from $27 and keeps a Buy rating on the shares. UBS sees meaningful upside to the stock if troriluzole is approved, and its base case models a 40% probability of success with an estimated PDUFA date in mid-November, the analyst tells investors in a research note.